首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Envelope variation as a primary determinant of lentiviral vaccine efficacy
【24h】

Envelope variation as a primary determinant of lentiviral vaccine efficacy

机译:包膜变异是慢病毒疫苗功效的主要决定因素

获取原文
获取原文并翻译 | 示例
       

摘要

Lentiviral envelope antigenic variation and associated immune evasion are believed to present major obstacles to effective vaccine development. Although this perception is widely assumed by the scientific community, there is, to date, no rigorous experimental data assessing the effect of increasing levels of lentiviral Env variation on vaccine efficacy. It is our working hypothesis that Env is, in fact, a primary determinant of vaccine effectiveness. We previously reported that a successful experimental attenuated equine infectious anemia virus vaccine, derived by mutation of the viral S2 accessory gene, provided 100% protection from disease after virulent virus challenge. Here, we sought to comprehensively test our hypothesis by challenging vaccinated animals with provi-ral strains of defined, increasing Env variation, using variant envelope SU genes that arose naturally during experimental infection of ponies with equine infectious anemia virus. The reference attenuated vaccine combined with these variant Env challenge strains facilitated evaluation of the protection conferred by ancestral immunogens, because the Env of the attenuated vaccine is a direct ancestor to the variant proviral strain Envs. The results demonstrated that ancestral Env proteins did not impart broad levels of protection against challenge. Furthermore, the results displayed a significant inverse linear correlation of Env divergence and protection from disease. This study demonstrates potential obstacles to the use of single isolate ancestral Env immunogens. Finally, these findings reveal that relatively minor Env variation can pose a substantial challenge to lentiviral vaccine immunity, even when attenuated vaccines are used that, to date, achieve the highest levels of vaccine protection.
机译:慢病毒包膜抗原变异和相关的免疫逃逸被认为是有效疫苗开发的主要障碍。尽管这种观点已被科学界广泛接受,但迄今为止,尚无严格的实验数据来评估慢病毒Env变异水平的提高对疫苗功效的影响。我们的工作假设是,Env实际上是疫苗效力的主要决定因素。我们以前曾报道过,成功的实验性减毒马传染性贫血病毒疫苗是通过病毒S2辅助基因的突变而衍生的,可在强病毒攻击后为疾病提供100%的保护。在这里,我们试图通过使用马感染性贫血病毒在小马实验性感染期间自然产生的变异包膜SU基因,通过具有确定的,增加的Env变异的原始病毒株对疫苗接种的动物进行挑战,来全面检验我们的假设。参比的减毒疫苗与这些变异的Env攻击菌株相结合,有助于评估祖先免疫原所赋予的保护作用,因为减毒疫苗的Env是变异的原病毒菌株Envs的直接祖先。结果表明,祖传的Env蛋白不能赋予广泛的保护水平以抵抗攻击。此外,结果显示Env散度与疾病防护之间存在显着的线性反相关。这项研究证明了使用单个分离祖先Env免疫原的潜在障碍。最后,这些发现表明,即使使用迄今为止达到最高疫苗保护水平的减毒疫苗,相对较小的Env变异也可能对慢病毒疫苗的免疫力构成重大挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号